Predict the Response to Acute Treatment of Migraine With Rimegepant 75 mg (NCT05888766) | Clinical Trial Compass
UnknownNot Applicable
Predict the Response to Acute Treatment of Migraine With Rimegepant 75 mg
Italy20 participantsStarted 2023-07-01
Plain-language summary
Tools to predict which patients could better respond to abortive CGRP target therapy are still lacking. We propose to investigate if biochemical (salivary CGRP) and neurophysiological (evoked potentials) biomarkers can recognize patients with the best chances of responding to Rimegepant 75 mg as an acute treatment of migraine.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Clinical diagnosis of Episodic migraine
* Prescription of Rimegepant 75 mg as abortive treatment for migraine
* headache occurring on \< 15 days/four weeks;
* No other primary/secondary headache disorder;
* No contraindication for Rimegepant 75 mg;
* No previous exposure to any anti-CGRP drugs;
* No prophylactic migraine treatment ongoing or in the past 3 months before participation in the study
Exclusion Criteria:
* headache occurring \>15 days/four weeks
* Contraindication for Rimegepant 75 mg
* Previous exposure to anti-CGRP drugs;
* Prophylactic migraine treatment ongoing or in the past 3 months before participation in the study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Salivary CGRP levels during attacks
Timeframe: from enrollment to one month after the start of therapy
2
Relationship between Rimegepant's response and salivary CGRP levels
Timeframe: from enrollment to one month after the start of therapy
3
Relationship between Rimegepant's response and habituation at baseline
Timeframe: from enrollment to one month after the start of therapy
4
Relationship between Rimegepant's response and sensitization at baseline
Timeframe: from enrollment to one month after the start of therapy